ImmunityBio (IBRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of ImmunityBio (IBRX)
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Key Insights
Critical company metrics and information
Share Price
$4.74Market Cap
$3.30 BillionTotal Outstanding Shares
696.83 Million SharesTotal Employees
672Dividend
No dividendIPO Date
March 10, 2021SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.immunitybio.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $375.24 Million |
| Net Cash Flow, Continuing | $-65.95 Million |
| Net Cash Flow From Investing Activities | $-19.83 Million |
| Net Cash Flow From Financing Activities, Continuing | $375.24 Million |
| Net Cash Flow | $-65.95 Million |
| Net Cash Flow From Operating Activities, Continuing | $-421.36 Million |
| Net Cash Flow From Operating Activities | $-421.36 Million |
| Net Cash Flow From Investing Activities, Continuing | $-19.83 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $595.25 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Operating Expenses | $367.50 Million |
| Operating Income/Loss | $-360.17 Million |
| Nonoperating Income/Loss | $-227.75 Million |
| Income Tax Expense/Benefit | $40000.00 |
| Research and Development | $206.46 Million |
| Basic Earnings Per Share | $0.90 |
| Income/Loss From Equity Method Investments | $0.00 |
| Net Income/Loss Attributable To Parent | $-587.79 Million |
| Income/Loss From Continuing Operations After Tax | $-587.88 Million |
| Selling, General, and Administrative Expenses | $160.16 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $86000.00 |
| Revenues | $7.33 Million |
| Diluted Earnings Per Share | $0.91 |
| Basic Average Shares | $738.90 Million |
| Net Income/Loss | $-587.88 Million |
| Diluted Average Shares | $742.58 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-587.79 Million |
| Income/Loss From Continuing Operations Before Tax | $-587.92 Million |
| Interest Expense, Operating | $120.72 Million |
| Costs And Expenses | $595.25 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $161.19 Million |
| Liabilities And Equity | $364.57 Million |
| Other Non-current Assets | $62.13 Million |
| Equity | $-744.16 Million |
| Liabilities | $1.11 Billion |
| Current Assets | $163.15 Million |
| Assets | $364.57 Million |
| Noncurrent Assets | $201.42 Million |
| Noncurrent Liabilities | $1.05 Billion |
| Equity Attributable To Noncontrolling Interest | $986000.00 |
| Current Liabilities | $60.96 Million |
| Equity Attributable To Parent | $-745.15 Million |
| Inventory | $1.96 Million |
| Fixed Assets | $139.28 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.